Description:

This lecture will outline and describe the current understanding of thyroid eye disease (TED) and its interrelation with Graves' Disease.  It will describe incidence, risk factors, and associated systemic signs, symptoms, and pathophysiology including Rundle's curve.  We will discuss treatment options for TED including the recent FDA approval of Teprotumumab, its clinical trials, study endpoints, and adverse reactions.  Masquerading ocular findings that may be early signs of TED will be described as well as lab testing that can help with the early detection of TED will be discussed.  Doctors have a knowledge need for this practice gap which means having the knowledge of how to detect, diagnose, and treat TED in an integrated, multidisciplinary method.

Course Code:

AOA255-SD

Speaker(s):

Jacob Lang, O.D.
drjakelang@gmail.com

Selina McGee, O.D.
drmcgee@bespokevision.org

Credits:

1

AOA Expiration Date:

4/20/2025

Related News

Optometry’s ‘pioneers’ come together to advance the profession

Nearly 300 optometric leaders met in the AOA’s headquarter city Jan. 30-Feb.1 to map its 2025 strategic direction.

Why thriving practices are prioritizing retirement plans

Offering a retirement plan is more than just an employee benefit; it’s a strategic move that can help your practice grow and succeed.